Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-03
DOI
10.1038/s41467-021-24878-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
- (2019) Kha-Liang Lee et al. Cancers
- Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice
- (2018) Ayumi Hashimoto et al. CANCER RESEARCH
- Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-Acute lymphoblastic leukemia
- (2018) Amol Padgaonkar et al. Oncotarget
- Self-renewal signaling pathways in breast cancer stem cells
- (2018) Lakshmi Vineela Nalla et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells
- (2017) Amber L. Rowse et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of casein kinase 2 blocks G2/M transition in early embryo mitosis but not in oocyte meiosis in mouse
- (2017) Fei LIN et al. JOURNAL OF REPRODUCTION AND DEVELOPMENT
- Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
- (2017) Fei Ma et al. MEDICINE
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype
- (2016) Kumiko Kida et al. BREAST CANCER RESEARCH AND TREATMENT
- Inhibition of casein kinase 2 prevents growth of human osteosarcoma
- (2016) Kengo Takahashi et al. ONCOLOGY REPORTS
- TNIK inhibition abrogates colorectal cancer stemness
- (2016) Mari Masuda et al. Nature Communications
- DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model
- (2015) N. Kurabayashi et al. EMBO REPORTS
- Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
- (2015) S K A Divakar et al. LEUKEMIA
- Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer
- (2015) Mari Masuda et al. PHARMACOLOGY & THERAPEUTICS
- The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation
- (2014) Ulf Soppa et al. CELL CYCLE
- ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24− phenotype
- (2014) Ying Zhong et al. MEDICAL ONCOLOGY
- Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway
- (2014) R T Nitta et al. ONCOGENE
- Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma
- (2013) Catarina Alisa Liebscher et al. HUMAN PATHOLOGY
- Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells
- (2013) Shulin Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle
- (2013) Jia-Yun Chen et al. MOLECULAR CELL
- Targeting CD44-STAT3 Signaling by Gemini Vitamin D Analog Leads to Inhibition of Invasion in Basal-Like Breast Cancer
- (2013) Jae Young So et al. PLoS One
- Global Screening of CK2 Kinase Substrates by an Integrated Phosphoproteomics Workflow
- (2013) Yangyang Bian et al. Scientific Reports
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
- (2012) A. Siddiqui-Jain et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of CK2α Down-Regulates Hedgehog/Gli Signaling Leading to a Reduction of a Stem-Like Side Population in Human Lung Cancer Cells
- (2012) Shulin Zhang et al. PLoS One
- The Germinal Center Kinase TNIK Is Required for Canonical NF-κB and JNK Signaling in B-Cells by the EBV Oncoprotein LMP1 and the CD40 Receptor
- (2012) Anna Shkoda et al. PLOS BIOLOGY
- Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
- (2011) I. A. Silva et al. CANCER RESEARCH
- CK2 functionally interacts with AKT/PKB to promote the β-catenin-dependent expression of survivin and enhance cell survival
- (2011) Daniela P. Ponce et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
- (2011) Fabrice Pierre et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
- (2010) Jingchun Gao et al. CANCER BIOLOGY & THERAPY
- Antitumor Activity of Pyridocarbazole and Benzopyridoindole Derivatives that Inhibit Protein Kinase CK2
- (2010) R. Prudent et al. CANCER RESEARCH
- CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
- (2010) A. Siddiqui-Jain et al. CANCER RESEARCH
- Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays
- (2010) Sophie Giusiano et al. EUROPEAN JOURNAL OF CANCER
- Structural basis of CX-4945 binding to human protein kinase CK2
- (2010) Andrew D. Ferguson et al. FEBS LETTERS
- Using Functional Genetics to Understand Breast Cancer Biology
- (2010) A. Ashworth et al. Cold Spring Harbor Perspectives in Biology
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- Protein Kinase CK2 in Health and Disease
- (2009) I. Dominguez et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells
- (2009) Giovanni Di Maira et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The kinase TNIK is an essential activator of Wnt target genes
- (2009) Tokameh Mahmoudi et al. EMBO JOURNAL
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- The emerging CK2 interactome: insights into the regulation and functions of CK2
- (2008) Laszlo Gyenis et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
- (2008) Ittai Ben-Porath et al. NATURE GENETICS
- Cancer stem cell markers in common cancers – therapeutic implications
- (2008) Thomas Klonisch et al. TRENDS IN MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More